Treatment of Huntington's Disease with Significant Unintended Weight Loss

Clinical Scenario

Patients with Huntington's disease frequently experience progressive nutritional decline. This protocol addresses the specific situation where unintended weight loss exceeds 10% over the preceding 3–6 months, or where BMI falls below 20 kg/m² with an accompanying unintentional weight loss of at least 5% over the same period.

In both cases, medical and/or social intervention is recommended to address the nutritional deficit and support disease management.

Clinical Goal

The primary target is to maintain a body mass index (BMI) within normal values — ideally on the higher end of the normal range — for as long as feasible given the patient's condition and trajectory.

Treatment Approach (Overview)

When significant weight loss is confirmed, the approach centres on supervised dietary intervention — including specialised food supplementation prescribed and monitored by a dietician or nutritionist. Dietary pattern may also play a role in supporting nutritional status. When pharmacological treatment is being initiated, the choice of agent takes into account its likely effect on body weight.

The complete evidence-based regimen — including specific supplementation guidance, dietary recommendations, and medication selection considerations — is available in the full protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.3389/fneur.2019.00710

A high Body Mass Index (BMI) within normal values should be maintained if possible and medical and/or social intervention is recommended when unintended weight loss is higher than 10% within last 3–6 months or when BMI is <20 kg/m² and unintentional weight loss of 5% is observed within last 3–6 months.

When weight loss is observed, high-calorie and high-protein food supplements should be prescribed under instruction and monitored by a dietician/nutritionist (Grade C).

A Mediterranean diet may improve Quality of Life and nutritional composition (Grade C).

In case of the initiation of antidepressant and/or neuroleptic treatments, treatments inducing weight gain should be preferred in patients with significant weight loss, whilst treatments inducing weight loss should be avoided (these effects can vary from one patient to another) (Grade C).

View source ↗